Barclays’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-4,600
| Closed | -$428K | – | 5824 |
|
|
2021
Q4 | $428K | Buy |
+4,600
| New | +$303K | ﹤0.01% | 3270 |
|
|
2020
Q4 | – | Sell |
-74,300
| Closed | -$5.56M | – | 5246 |
|
|
2020
Q3 | $5.56M | Buy |
+74,300
| New | +$4.95M | ﹤0.01% | 1335 |
|
|
2018
Q2 | – | Sell |
-189,500
| Closed | -$7.49M | – | 7437 |
|
|
2018
Q1 | $7.49M | Buy |
189,500
+168,200
| +790% | +$6.54M | 0.01% | 1347 |
|
|
2017
Q4 | $723K | Hold |
21,300
| – | – | ﹤0.01% | 3449 |
|
|
2017
Q3 | $543K | Buy |
21,300
+7,500
| +54% | +$172K | ﹤0.01% | 3545 |
|
|
2017
Q2 | $233K | Buy |
13,800
+11,980
| +658% | +$164K | ﹤0.01% | 4248 |
|
|
2017
Q1 | $27K | Sell |
1,820
-4,730
| -72% | -$70.1K | ﹤0.01% | 5680 |
|
|
2016
Q4 | $93K | Sell |
6,550
-1,160
| -15% | -$18K | ﹤0.01% | 4802 |
|
|
2016
Q3 | $135K | Sell |
7,710
-1,860
| -19% | -$30.8K | ﹤0.01% | 4290 |
|
|
2016
Q2 | $164K | Buy |
9,570
+6,040
| +171% | +$108K | ﹤0.01% | 4073 |
|
|
2016
Q1 | $35K | Sell |
3,530
-12,940
| -79% | -$207K | ﹤0.01% | 4969 |
|
|
2015
Q4 | $165K | Buy |
16,470
+1,230
| +8% | +$25.1K | ﹤0.01% | 4066 |
|
|
2015
Q3 | $153K | Sell |
15,240
-1,010
| -6% | -$34.3K | ﹤0.01% | 4322 |
|
|
2015
Q2 | $650K | Buy |
16,250
+9,200
| +130% | +$399K | ﹤0.01% | 3255 |
|
|
2015
Q1 | $282K | Sell |
7,050
-28,660
| -80% | -$1.33M | ﹤0.01% | 4092 |
|
|
2014
Q4 | $1.07M | Buy |
35,710
+20
| +0.1% | +$812 | ﹤0.01% | 3153 |
|
|
2014
Q3 | $1.43M | Sell |
35,690
-148,920
| -81% | -$6.65M | ﹤0.01% | 2981 |
|
|
2014
Q2 | $9.23M | Buy |
184,610
+77,090
| +72% | +$4.85M | 0.01% | 1219 |
|
|
2014
Q1 | $6.45M | Buy |
107,520
+50,880
| +90% | +$3.38M | 0.01% | 1510 |
|
|
2013
Q4 | $2.83M | Sell |
56,640
-6,790
| -11% | -$355K | ﹤0.01% | 2324 |
|
|
2013
Q3 | $3.17M | Sell |
63,430
-86,880
| -58% | -$5.83M | ﹤0.01% | 2110 |
|
|
2013
Q2 | $11.6M | Buy |
+150,310
| New | +$12.3M | 0.01% | 984 |
|
Barclays's ARNA Position: Q1 2022 in Review
Barclays sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 149,859 shares — an estimated $13.9M sold.
Barclays first reported a position in ARNA in Q2 2013 and held it in 35 quarters. The position peaked at $13.9M in Q4 2021. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Barclays reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Barclays sold 149,859 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $13.9M.
- Barclays first reported a position in Arena Pharmaceuticals Inc in Q2 2013 and held it in 35 quarters.
- Barclays's Arena Pharmaceuticals Inc position peaked at $13.9M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Barclays's 13F filing for Q1 2022, filed 16 May 2022.